Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
vaccine
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03942328CT.gov Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intrahepatic Cholangiocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| PCV 13 (this asset) | Mayo Clinic | P1/2 | CCC · 48 |
| Nivolumab | Virogin Biotech Canada Ltd | P2 | BB |
| Durvalumab | West China Hospital | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Shanghai 6th People's Hospital | P2 | BB |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | B |
| Atezolizumab | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | TriSalus Life Sciences, Inc. | P2 | B |
| Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | P2 | B |
| Pembrolizumab | Shanghai 6th People's Hospital | P1/2 | B |
+42 more in the Intrahepatic Cholangiocarcinoma cohort
Other indications for PCV 13
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pneumococcal Infection | — | P3 | BB · 64 |
| Relapsing-Remitting Multiple Sclerosis | — | P3 | B · 60 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. PCV 13 in Intrahepatic Cholangiocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pcv-13-intrahepatic-cholangiocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →